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Abstract: Cisplatin is a DNA-damaging anti-cancer agent that is widely used to treat a range of tumour types. Despite its 
clinical success, cisplatin treatment is still associated with a number of dose-limiting toxic side effects. The purpose of this 
study was to clarify the molecular events that are important in the anti-tumour activity of cisplatin, using gene expression 
proﬁ  ling techniques. Currently, our incomplete understanding of this drug’s mechanism of action hinders the development 
of more efﬁ  cient and less harmful cisplatin-based chemotherapeutics. In this study the effect of cisplatin on gene expression 
in human foreskin ﬁ  broblasts has been investigated using human 19K oligonucleotide microarrays. In addition its clinically 
inactive isomer, transplatin, was also tested. Dual-ﬂ  uor microarray experiments comparing treated and untreated cells were 
performed in quadruplicate. Cisplatin treatment was shown to signiﬁ  cantly up- or down-regulate a consistent subset of 
genes. Many of these genes responded similarly to treatment with transplatin, the therapeutically inactive isomer of cispla-
tin. However, a smaller proportion of these transcripts underwent differential expression changes in response to the two 
isomers. Some of these genes may constitute part of the DNA damage response induced by cisplatin that is critical for its 
anti-tumour activity. Ultimately, the identiﬁ  cation of gene expression responses unique to clinically active compounds, like 
cisplatin, could thus greatly beneﬁ  t the design and development of improved chemotherapeutics.
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Introduction
The DNA-damaging agent, cis-diamminedichloroplatinum (II), cisplatin, is used extensively as a 
chemotherapeutic drug. In particular, it is successfully employed to treat ovarian and testicular carci-
nomas, as well as a range of other solid tumours (Adams et al. 1998; De Pree and Wils, 1989). However, 
dose-limiting toxic side effects and the occurrence of both acquired and intrinsic drug resistance in cells 
impose great limitations on cisplatin chemotherapy (Kelland, 2000; Siddik, 2003). While concerted 
efforts have been made towards developing cisplatin analogues with improved chemotherapeutic efﬁ  -
cacy and reduced toxic side effects, only a few compounds have been clinically registered—the most 
notable of these being carboplatin and oxaliplatin (Hartmann and Lipp, 2003).
A major factor contributing to the current status of rationally designed analogues is a relatively poor 
understanding of the speciﬁ  c molecular events associated with cisplatin-induced tumour cell death. 
Although its detailed mechanism of action is presently unclear, it is generally thought that the covalent 
binding of cisplatin to cellular DNA and subsequent formation of bulky DNA adducts, mediate the 
cytotoxicity of this anti-cancer agent (Rosenberg, 1985; Wang and Lippard, 2005). Intra-strand DNA 
cross-links are the most common adducts formed, although inter-strand DNA cross-links and DNA-
protein cross-links can also occur (Fichtinger-Schepman et al. 1985; Lippard and Hoeschele, 1979). 
The intra-strand DNA lesions preferentially form between the N-7 of adjacent guanine residues, inhibiting 
the passage of polymerases and thus interfering with DNA replication and RNA transcription inside 
target cells (Corda et al. 1992; Murray et al. 1992; Murray et al. 1998; Roberts and Thomson, 1979). 
While the general inhibition of RNA synthesis reduces the mRNA levels of many genes, an active cel-
lular response to cisplatin damage can inﬂ  uence gene expression both positively and negatively and to 
varying extents, depending on the promoter (Evans and Gralla, 1992).
The active response to such drug-induced DNA damage consists of two key processes. These include 
the repair of DNA damage through the removal of cisplatin adducts and, where repair cannot be carried 316
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out successfully, the induction of cell death via 
apoptosis. While DNA repair and apoptotic path-
ways are considered to play the most signiﬁ  cant role 
in determining cisplatin’s cytotoxic effect, various 
non-speciﬁ  c events associated with the drug-DNA 
interaction should also be taken into account. These 
non-specific events arise as consequences of 
cisplatin-DNA adduct formation and the overall 
inhibition of  DNA and RNA synthesis. In addition, 
altered gene expression could also result from 
cisplatin-protein interactions (Perez, 1998) and the 
sequestration of transcription factors by cisplatin-
DNA adducts. At present, little is known about the 
extent to which each of these active and non-speciﬁ  c 
responses contribute to cisplatin-induced cell death. 
This issue is addressed in the main aim of this work, 
which is to determine whether the regulation of 
speciﬁ  c genes in response to cisplatin treatment is 
crucial to the drug’s anti-tumour activity.
Oligonucleotide microarrays containing approx-
imately nineteen thousand human genes were used 
to examine the broad effect of cisplatin on gene 
expression in human foreskin ﬁ  broblasts. The 
response of such a non-cancer cell line to DNA 
damage was considered to be particularly signiﬁ  -
cant since most toxic side effects are due to the 
exposure of normal cells to the anti-tumour drug 
during chemotherapy. The gene expression proﬁ  les 
derived from these cells indicated that many genes 
consistently exhibited altered gene expression pat-
terns due to cisplatin treatment. Rigorous methods 
for analysing the resulting microarray data were 
developed. Thorough normalisation techniques and 
a statistically robust procedure for estimating the 
significance of gene expression changes were 
implemented via the statistical computing environ-
ment, “R”. Using the software package, EASE, a 
method for exploring the biological themes among 
differentially expressed transcripts was also inves-
tigated. An attempt to clarify whether any of these 
molecular events are crucial to cisplatin’s anti-
tumour activity was made by constructing similar 
expression proﬁ  les for the clinically inactive cis-
platin isomer, transplatin (Fig. 1). Both compounds 
were found to consistently induce a common sub-
set of gene responses in ﬁ  broblasts. However, 
thorough one- and two-sample statistical com-
parisons also indicated that several genes had 
signiﬁ  cantly different expression levels in cisplatin-
treated cells compared to transplatin-treated cells. 
The identiﬁ  cation of gene expression responses 
unique to clinically active compounds, such as 
cisplatin, could have a range of implications on the 
design and development of improved 
chemotherapeutics.
Materials and Methods
Materials
Cisplatin, transplatin and Tri-Reagent were pur-
chased from Sigma. Cell culture reagents and 
Superscript (II) Reverse Transcriptase were obtained 
from Invitrogen. Alamar Blue reagent was pur-
chased through Astral Scientiﬁ  c. RNeasy columns 
were obtained from Qiagen. Cy3 and Cy5 mono-
reactive fluorescent dyes were purchased from 
Amersham Biosciences. Human 19K oligonucle-
otide microarrays were produced by and purchased 
from The Clive and Vera Ramaciotti Centre for Gene 
Function Analysis, University of NSW.
Cell Culture Conditions
The non-transformed human foreskin ﬁ  broblast cell 
line, FFbw002, was kindly donated by Noel Whita-
ker. Cells were grown in RPMI (Rosewell Park 
Memorial Institute) medium supplemented with 10% 
fetal bovine serum and maintained at 37 °C and 5% 
CO2 in a humidiﬁ  ed incubator. Fibroblasts in log-
phase growth were harvested prior to sub-culturing 
and drug treatment using mild trypsinisation.
Cytotoxicity Assay
Cytotoxicity determinations for cisplatin and trans-
platin were performed using an Alamar Blue
TM 
assay. FFbw002 Human foreskin ﬁ  broblasts were 
seeded at a density of 2 × 10
5 cells/ml in 96-well, 
ﬂ  at-bottomed microtitre plates in 100 µl of RPMI 
medium. Drugs (diluted in DMF) and controls were 
administered to cells in 100 µl of RPMI to give the 
ﬁ  nal concentrations indicated: cisplatin (0.1mM to 
100mM), transplatin (0.1 µM to 100 µM) and DMF 
(0.01% to 8% (v/v)). At least three replicates were 
performed for each administration. The plates were 
incubated at 37 °C in a humidiﬁ  ed cell culture 
chamber with 5% CO2 for 5 hours. Twenty µl of 
Alamar Blue
TM reagent was then added to each 
well and the plates were incubated for a further 
3 hours. At this time, absorbance readings of the 
plates were immediately recorded using a Bench-
mark plate-reader with a sample wavelength of 
570 nm and a reference of 595 nm. Following this 317
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eight-hour time point, plates were returned to the 
incubator and further absorbance readings were 
taken at 24 hours. Cell survival in the presence of 
drug was expressed as a percentage of cell growth 
in the drug-free DMF control corresponding to 
the% DMF in the drug treatment.
Drug Treatment and Total RNA 
Extraction
Harvested ﬁ  broblasts were incubated at a concen-
tration of approximately 5 × 10
6 cells/ml RPMI 
medium, with varying concentrations of cisplatin 
or transplatin (each diluted in DMF), for 5 hours 
at 37 °C with 5% CO2. Total RNA was then isolated 
from cells using Tri-Reagent and the accompany-
ing protocol for extracting total RNA from cultured 
cells (issued by Sigma). The integrity of total RNA 
was assessed using 1% agarose gel electrophoresis 
and its approximate concentration and purity esti-
mated via UV spectrophotometry.
cDNA Synthesis and Hybridisation
cDNA was synthesised using approximately 50 µg 
of total RNA in an oligo-dT(20mer)-primed reverse 
Transplatin
Pt
Cl
Cl
NH3
NH3
Pt
Cl NH3
Cl
Cisplatin
H3N
Figure 1. The chemical structures of cisplatin and transplatin. The main focus of this study is the mechanism of action of the DNA-
damaging anti-cancer drug, cisplatin. Although structurally similar, cisplatin’s isomer, transplatin, lacks the anti-tumour activity exhibited by 318
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transcription reaction with Superscript II Reverse 
Transcriptase (Invitrogen). RNA was combined 
with 8 µl of 5x First Strand Superscript II Buffer 
(Invitrogen), 0.4nmol oligo-dT20, 10 µM DTT and 
made up to 32.2 µl with RNase-free H2O. Reactions 
were incubated for 5 minutes at 65 °C followed by 
5 minutes at 42 °C. While at 42 °C, dATP, dGTP 
and dCTP nucleotides were added at a final 
concentration of 0.5 µM each, along with dTTP at 
0.16 µM, aa(aminoalyl)-dUTP at 0.34 µM and 2 µl 
Superscript II Reverse Transcriptase. Reactions 
were then incubated for a further 2.5 hours at 42 °C. 
RNA was hydrolysed with the addition of 4ml of 
50mM EDTA (pH8) and 2 µl of 10M NaOH to each 
sample, followed by an incubation of 20 minutes 
at 65 C. Reactions were neutralised with 4 µl of 5M 
acetic acid and then each sample was puriﬁ  ed using 
a separate QIAquick PCR purification column 
(Qiagen). To couple mono-reactive ﬂ  uorescent Cy-
dyes (Amersham Biosciences) to the aminoalyl-
dUTP moieties in target cDNA molecules, 9 µl of 
0.1M NaHCO3 (pH9) and 2 µl of Cy5 (control 
samples) or Cy3 (drug-treated samples) were mixed 
with the appropriate samples. These reactions were 
left to incubate in a dark environment for 45 minutes 
at room temperature and then puriﬁ  ed as above, 
using a separate QIAquick PCR puriﬁ  cation column 
(Qiagen) for each sample. Hybridisation buffer was 
prepared with yeast tRNA (Sigma) at approximately 
0.5 mg/ml and calf thymus DNA (Sigma) at 
approximately 0.5 mg/ml in DIG Easy Hyb (Roche). 
Concentrated Cy5(control) and Cy3(drug-treated) 
cDNA samples to be compared were combined 
directly with hybridisation buffer to a ﬁ  nal volume 
of approximately 92 µl, heated for 5 minutes at 
65 C and then allowed to cool to room temperature. 
Hybridisation mixtures were applied directly to 
microarray slides (Human 19K oligonucleotide 
arrays), each covered with a LifterSlip
TM coverglass 
(ProSciTech) and then hybridised at 37 °C overnight 
(approximately 16 hours) in a humidiﬁ  ed custom-
made hybridisation chamber. LifterSlips
TM were 
removed in 1 × SSC and slides washed three times 
in 1 × SSC/0.1% SDS at 50 °C. A ﬁ  nal rinse in 
1 × SSC was immediately followed by 10 minutes 
of centrifugation at 500 g to dry slides in preparation 
for scanning.
Microarray Scanning, Data Acquisition 
and Processing
Microarrays were scanned using an Axon 4000A 
laser-based scanner and image data was acquired 
through associated GenePix Pro 3.0 software. Further 
data manipulation and statistical analyses (see below) 
were undertaken in the R statistical computing 
environment (www.r-project.org) with additional 
microarray-speciﬁ  c R-packages available from the 
BioConductor project (www.bioconductor.org). The 
R-function, marrayGUI, constructed by Mr Chris 
Bye (Westmead Millennium Institute) was used to 
input data into the R environment. Preliminary data 
processing involved the assignment of spot quality 
‘weights’ to all data points. A “Robust Spline” 
method of intra-array normalisation (limma package 
in BioConductor), which utilises the spot quality 
weights determined above, was then applied to each 
slide. This approach accounts for both spatial- and 
intensity-dependent biases by fitting regression 
splines through data from individual print-tip groups 
and employing Empirical Bayes methods to shrink 
the print-tip curves towards a common value. 
Compared to standard “Print-tip Loess” normalisation 
procedures, such a technique is believed to introduce 
less “noise” into fairly good quality arrays that have 
little spatial variation. At this stage, unreliable data 
from spots with low quality weights due to low signal 
intensities or high spot background intensities was 
mostly ﬁ  ltered out so as to be excluded from further 
statistical analyses.
Statistical Evaluation of Differential 
Gene Expression
Functions within the limma package in BioConduc-
tor were ﬁ  rstly employed to calculate a log-odds of 
differential expression (B-statistic) for each gene. 
This involved the ﬁ  tting of gene-wise linear models 
through selected data and Empirical Bayes mod-
eration of corresponding t-statistics. ‘One-’ and 
‘Two-sample’ experimental design matrices were 
structured to allow the simultaneous assessment of 
differential expression within and between experi-
mental conditions (microarray groups), respec-
tively. The magnitudes of resulting B-statistics were 
then used to rank genes in order of evidence for 
differential expression. Transcripts considered to 
have a signiﬁ  cant level of differential expression 
within a single test comparison (e.g. control vs 
treatment 1), were those highly ranked according 
to ‘one-sample’ B-statistic magnitudes and with 
average fold-changes greater than 1.4. Alternative 
procedures for multiple hypothesis testing available 
within the multtest package in BioConductor, were 
also investigated. In an ANOVA framework, 319
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F-statistics were calculated for each transcript using 
log expression ratio data from the three main test 
comparisons. As for the B-statistics, the magnitudes 
of these test-statistics were then used directly to 
identify transcripts most likely to be differentially 
expressed between the three test conditions.
Gene Categories Over-represented 
Among Differentially Expressed 
Transcripts
Analysis tools implemented within the software 
package EASE (Expression Analysis Systematic 
Explorer) were used to annotate differentially 
expressed transcripts and explore the “biological 
themes” of signiﬁ  cant gene subsets. EASE is freely 
available through the URL http://david.niaid.nih.
gov/david/ease.htm.
Results
The human gene expression response to cisplatin 
treatment was investigated using transcription 
proﬁ  ling techniques. The use of oligonucleotide 
microarrays permitted the gene expression levels 
of many genes to be monitored simultaneously.
A human foreskin fibroblast cell line was 
employed and gene expression proﬁ  les were com-
piled for both cisplatin and its clinically ineffective 
isomer, transplatin. The transcriptional response 
of ﬁ  broblasts to drugs with different anti-tumour 
efﬁ  ciencies could then be investigated.
Alamar Blue
TM cytotoxicity assays
Fibroblasts were ﬁ  rstly subjected to cytotoxicity 
assays with cisplatin and transplatin to determine 
optimal treatment conditions for inducing a clini-
cally relevant gene expression response. Fibro-
blasts were initially incubated at 37°C with drugs 
(or without drugs or controls) for 5 hours. At this 
time point, t = 5 hours, Alamar Blue
TM reagent was 
added to each sample. Absorbance measurements 
were then taken at t = 8 and 24 hour time points 
and used to indicate the proportion of living cells 
remaining in each sample. Graphs in Figure 2 
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Figure 2. AlamarBlueTM Cytotoxicity Assay: Human ﬁ  broblasts treated with cisplatin and transplatin. Graphs indicate the % Cell 
Survival at (a) 8 and (b) 24 hours for 0.1–100µM Cisplatin and Transplatin. The data points shown are for drug concentrations of 0.1, 0.3, 
1.0, 10, 25 and 100 µM, and have been averaged across three replicate values. Error bars represent the standard error of the mean. (Note: 
Scale of x-axis is in logarithmic format).320
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depict the percentage cell survival values deter-
mined for ﬁ  broblasts treated with 0.1-100 µM 
cisplatin or transplatin for 8 and 24 hours.
The cytotoxicity assay results for this particular 
ﬁ  broblast cell line indicated that there was a small 
to moderate difference between the cytotoxic 
effects elicited by cisplatin and transplatin. At the 
8 hour time point, cisplatin was more toxic than 
transplatin at concentrations up to at least 25 µM. 
At 100 µM doses, transplatin appeared to induce 
slightly higher levels of cell death. For the 24 hour 
time point, however, cisplatin was consistently 
more cytotoxic to cells at all concentrations exam-
ined. Overall, drug concentrations ranging between 
0.1 and 25 µM produced relatively low levels of 
cell death during both incubation periods. Within 
this dose range, the average cell survival estimates 
were 90% for cisplatin treatments and 95% for 
transplatin treatments. At drug concentrations 
above 25 µM, however, the cytotoxic effect of both 
compounds was more apparent.
In considering these results and those of the 
preliminary investigations, subsequent gene 
expression studies were conducted using 5 hour 
treatments with 1 µM cisplatin or transplatin. At 
this concentration, the cytotoxicity assay indicated 
that there was a slight difference between the toxic 
effects of the two isomers. To allow gene expres-
sion responses to equitoxic drug doses to be 
studied, a second transplatin concentration of 
25 µM was also chosen for comparison. At this 
8 hour dose, transplatin’s level of toxicity was 
approximately equivalent to that of 1 µM cisplatin. 
Similar differences in concentration have been 
required to achieve equitoxic cisplatin and trans-
platin doses in other studies (Burczynski et al. 
2000; Sanchez-Perez et al. 1998; Sato et al. 1996). 
Furthermore, this concentration represented the 
lowest dose at which cytotoxicity levels were 
relatively low for both drugs.
Microarray experiments, 
data acquisition and normalisation
All cell treatments were performed in quadruplicate. 
Total RNA was extracted from each cell population 
and used to synthesise ﬂ  uorescently-labelled cDNA. 
cDNA samples derived from different treatments 
were then compared directly using human oligo-
nucleotide microarrays containing approximately 
19,000 human gene sequences and control ele-
ments. Microarray experiments, also carried out in 
quadruplicate, were performed for each of the 
following comparisons: DMF (control) vs 1 µM 
Cisplatin, DMF vs 1 µM Transplatin, DMF vs 25 µM 
Transplatin, 1 µM Transplatin vs 1 µM Cisplatin and 
25 µM Transplatin vs 1 µM Cisplatin.
Following microarray scanning and data acqui-
sition, raw results were processed and normalised 
as described in section 2.3.12. During these 
manipulations, the red and green ﬂ  uorescence 
intensities were normalised relative to one another 
so that the green/red ratios approached an unbiased 
representation of relative expression levels. The 
ultimate aim of the normalisation process was to 
remove or reduce any systematic biases or errors 
in the results that were not due to the experimental 
condition(s) of interest (Smyth and Speed, 2003). 
In the current study, a “Robust Spline” method of 
intra-array normalisation was applied to data from 
each microarray using the limma (Linear Models 
for Microarray Data) package in BioConductor. 
The incorporation of spot quality weights deter-
mined in the preprocessing step (section 2.3.12(i)) 
controlled the extent to which each data point 
contributed to the normalisation calculations. This 
meant that unreliable data from spots with low 
quality weights due to low foreground or high 
background intensities were filtered out and 
excluded from the analysis. The “Robust Spline” 
function also accounted for both spatial- and 
intensity-dependent biases in the microarray data 
(Smyth and Speed, 2003; Yang et al. 2002).
‘MA-plots’, as described by Yang et al., 2002, 
provided a convenient graphical means of repre-
senting the red (R) and green (G) ﬂ  uorescence 
intensity data for each gene on the array. Within 
these plots, M(y-axis) = log2(R/G) and A(x-axis) = 
log2v(R × G). Thus, for each gene on the array, ‘M’ 
essentially describes the ﬂ  uorescence intensity 
ratio, while ‘A’ represents the relative combined 
ﬂ  uorescence intensity (Yang et al. 2002). Figure 3 
shows a representative MA-plot for the normalised 
background-corrected data from DMF vs 1 µM 
Cisplatin treatment comparisons. Human gene 
transcripts with relatively up- or down-regulated 
expression levels due to cisplatin treatment are 
located below or above the ‘M = 0’ horizontal axis, 
respectively. In this study, MA-plots were particu-
larly valuable in terms of identifying spot artifacts 
(or irregularities) and intensity-dependent trends in 
the log ratios (M-values). They were also employed 
for the purpose of monitoring and assessing the data 
normalisation procedures described above.321
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Statistical signiﬁ  cance 
evaluation – Overview
Having normalised the microarray data, the next 
step was to develop a statistically robust approach 
for deﬁ  ning differentially expressed transcripts. 
When examining such large sets of gene expression 
data, it is particularly crucial to address this issue 
since observed changes in expression may not 
always be a direct consequence of the test condi-
tions. For example, altered expression patterns may 
result from variations in the data acquisition proce-
dures or biologically insignificant fluctuations 
within the original cell populations that are not 
speciﬁ  cally related to the experimental conditions 
of interest. While many expression studies use a 
two-fold change in expression as the lower limit of 
signiﬁ  cant gene expression changes, this approach 
can exclude valuable data and is not statistically 
ﬂ  exible for use across multiple arrays. Instead, the 
current study adopted a statistically rigorous method 
for estimating and ranking the relative signiﬁ  cance 
of observed gene expression changes.
Conducted within ‘R’, the main statistical pro-
cedure for deﬁ  ning differential expression imple-
mented functions from the limma analysis package 
in BioConductor. These functions effectively 
facilitated the simultaneous analysis of compari-
sons between multiple RNA targets (that is, dif-
ferentially-labelled cDNA populations). The key 
to this approach was a “design matrix” which was 
used to specify the desired treatments for com-
parison. This meant that data from multiple arrays 
could thus be examined simultaneously. The result 
was a log-odds of differential expression, or 
B-statistic, which was estimated for each gene in 
each treatment comparison. B-statistic magnitudes 
were then used to rank genes in order of evidence 
for differential expression.
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tive intensity) values were averaged across 4 replicate microarrays. M values greater than zero indicate transcripts which responded to cisplatin with 
decreased expression levels, while M values less than zero indicate transcripts with increased expression levels after cisplatin treatment.322
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Using the linear model approach described 
above, a “one-sample comparison” experimental 
design matrix was used to examine differential 
expression within separate microarray groups, 
where each ‘group’ represents one comparison 
performed on four replicate microarrays:
Group 1. DMF vs 1 µM cisplatin
Group 2. DMF vs 1 µM transplatin
Group 3. DMF vs 25 µM transplatin
Group 4. 1 µM transplatin vs 1 µM cisplatin
Group 5. 25 µM transplatin vs 1 µM cisplatin.
B-statistics were computed for all ﬁ  ve com-
parisons. Genes with the highest B-statistics thus 
had the highest likelihood of being differentially 
expressed within each group. Next, data from the 
ﬁ  rst three microarray groups was combined within 
a “two-sample comparison” design matrix. This 
technique was employed to assess the extent of 
differential expression between microarray groups, 
and thus between treatments. For example, the 
simultaneous analysis of Group 1 and Group 3 data 
revealed over 200 genes that were highly ranked 
for differential expression between the 1 µM cis-
platin and 25 µM transplatin treatments. Following 
both one- and two-sample comparison B-statistic 
analyses, the ‘EASE’ software package was 
employed to search for over-represented gene 
categories amongst differentially expressed genes. 
This procedure allowed the biological themes of 
signiﬁ  cant gene subsets to be investigated. In the 
subsequent sections of this chapter, the results of 
B-statistic analyses and over-representation studies 
are presented and discussed in further detail.
One-sample comparison B-statistic 
analysis
One-sample comparison B-statistic analyses were 
successfully employed to estimate the relative 
signiﬁ  cance of ‘apparent’ changes in gene expres-
sion levels between control and drug-treated 
samples. Transcripts with B-statistic values greater 
than zero were deﬁ  ned as exhibiting signiﬁ  cantly 
different expression levels in response to treatment, 
while the highest B-statistics indicated genes with 
the highest likelihood of being differentially 
expressed. This study revealed many genes that 
were differentially expressed in each of the three 
treatments examined: 1 µM cisplatin, 1 µM and 
25 µM transplatin (see Table 1). For example, in 
cisplatin-treated cells, 1227 transcripts were found 
to exhibit signiﬁ  cantly higher expression levels, 
while 316 transcripts were classed with signiﬁ  -
cantly lower expression levels. Table 2 describes 
the ﬁ  rst 20 known genes that were signiﬁ  cantly 
up- and down-regulated in response to 1 µM cis-
platin. As might be expected, many of the differ-
entially expressed transcripts were common to 
cisplatin and transplatin treatments, indicating 
some degree of consistency in the transcriptional 
response to both platinum isomers. Some of the 
transcriptional events common to all three 
treatments are also indicated in Table 2.
Using the expression analysis program, EASE, 
gene annotation tools were next employed to iden-
tify gene categories that were over-represented in 
each differentially expressed gene subset compared 
to what was represented on the microarrays. Indi-
vidual gene categories were also classed into one 
of the following gene ontology (GO) systems: 
molecular function, biological process or cellular 
component. In each analysis, the gene category 
with the lowest ‘EASE score’ was considered to 
be the most ‘over-represented’ or signiﬁ  cant cat-
egory within that subset of differentially expressed 
transcripts. The ﬁ  rst 20 most over-represented gene 
categories among transcripts up- and down-
regulated by 1mM cisplatin are shown in Table 3. 
As indicated, most of these categories were also 
over-represented among the signiﬁ  cant transcripts 
of transplatin treatments. It is thus possible that 
many of the genes associated with these molecular 
functions and biological processes are involved in 
a more general response to the toxic insult.
One-sample B-statistics were also calculated 
for the Group 4 and Group 5 microarray data: 1 µM 
transplatin vs 1 µM cisplatin and 25 µM transpla-
tin vs 1 µM cisplatin. However, this analysis 
largely yielded negative B-statistic values, imply-
ing that there were no significant differences 
between the transcriptional responses to each treat-
ment. Another possibility was that variations 
between the treatment-speciﬁ  c gene expression 
proﬁ  les were of a magnitude that could not be 
resolved using this technique, especially in the 
presence of relatively large systematic errors and 
inherent dye biases. While dye-swapping or recip-
rocal labelling techniques are often employed in 
attempts to counteract such biases, this approach 
is more amenable to microarray experiments in 
which the differences between cDNA populations 
are of a higher magnitude (for example, when 
comparing different cell lines). In the current study, 
the average ‘significant’ drug-induced gene 323
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a
l
a
c
t
o
s
i
d
e
-
b
i
n
d
i
n
g
,
 
s
o
l
u
b
l
e
,
 
7
 
(
g
a
l
e
c
t
i
n
 
7
)
 
(
L
G
A
L
S
7
)
 
m
R
N
A
2
.
3
1
3
.
7
0
7
1
.
2
0
6
0
.
0
0
1
0
8
M
8
7
9
4
1
H
u
m
a
n
 
c
a
r
c
i
n
o
m
a
 
c
e
l
l
-
d
e
r
i
v
e
d
 
A
l
u
 
R
N
A
 
t
r
a
n
s
c
r
i
p
t
,
 
c
l
o
n
e
 
A
L
U
2
0
2
.
4
8
3
.
4
6
8
1
.
3
0
1
0
.
0
0
1
2
2
N
M
_
0
1
5
8
8
5
P
C
F
1
1
p
 
h
o
m
o
l
o
g
 
(
L
O
C
5
1
5
8
5
)
,
 
m
R
N
A
1
.
9
1
3
.
4
3
5
0
.
9
2
5
0
.
0
0
1
1
0
A
F
0
4
0
2
4
7
e
r
y
t
h
r
o
i
d
 
d
i
f
f
e
r
e
n
t
i
a
t
i
o
n
-
r
e
l
a
t
e
d
 
f
a
c
t
o
r
 
1
 
m
R
N
A
,
 
p
a
r
t
i
a
l
 
c
d
s
3
.
0
7
3
.
3
7
9
1
.
5
7
3
0
.
0
0
1
3
0
M
9
2
2
7
3
H
u
m
a
n
 
d
i
h
y
d
r
o
p
y
r
i
d
i
n
e
-
s
e
n
s
i
t
i
v
e
 
c
a
l
c
i
u
m
 
c
h
a
n
n
e
l
 
H
F
C
C
,
 
3
'
-
e
n
d
 
i
n
t
r
o
n
 
4
2
.
3
0
3
.
2
7
2
1
.
2
0
0
0
.
0
0
1
3
3
N
M
_
0
0
5
0
6
6
s
p
l
i
c
i
n
g
 
f
a
c
t
o
r
 
p
r
o
l
i
n
e
/
g
l
u
t
a
m
i
n
e
 
r
i
c
h
 
(
p
o
l
y
p
y
r
i
m
i
d
i
n
e
 
t
r
a
c
t
-
b
i
n
d
i
n
g
 
p
r
o
t
e
i
n
-
a
s
s
o
c
i
a
t
e
d
)
 
(
S
F
P
Q
)
 
m
R
N
A
1
.
7
0
3
.
1
9
1
0
.
7
6
8
0
.
0
0
1
2
3
U
6
2
8
2
3
H
u
m
a
n
 
s
m
a
l
l
 
n
u
c
l
e
a
r
 
R
N
A
 
U
6
a
t
a
c
,
 
p
a
r
t
i
a
l
 
s
e
q
u
e
n
c
e
1
.
7
7
3
.
0
2
9
0
.
8
2
6
0
.
0
0
1
3
3
Y
1
0
2
0
6
H
.
s
a
p
i
e
n
s
 
m
R
N
A
 
f
o
r
 
C
D
6
4
 
p
r
o
t
e
i
n
3
.
3
7
2
.
9
4
3
1
.
7
9
1
0
.
0
0
1
5
8
N
M
_
0
1
2
3
4
8
o
l
f
a
c
t
o
r
y
 
r
e
c
e
p
t
o
r
 
8
9
 
(
O
L
F
R
8
9
)
,
 
m
R
N
A
2
.
2
8
2
.
9
0
2
1
.
1
7
8
0
.
0
0
1
6
1
X
9
6
6
4
4
H
.
s
a
p
i
e
n
s
 
m
R
N
A
 
f
o
r
 
U
4
5
a
 
s
m
a
l
l
 
n
u
c
l
e
a
r
 
R
N
A
2
.
1
2
2
.
7
9
1
1
.
0
8
3
0
.
0
0
1
6
6
A
Y
0
1
0
1
1
1
c
a
d
h
e
r
i
n
-
2
3
 
(
C
D
H
2
3
)
 
m
R
N
A
,
 
p
a
r
t
i
a
l
 
c
d
s
2
.
1
7
2
.
5
1
3
1
.
1
1
3
0
.
0
0
1
8
7
U
5
0
5
3
9
H
u
m
a
n
 
B
R
C
A
2
 
r
e
g
i
o
n
,
 
m
R
N
A
 
s
e
q
u
e
n
c
e
 
G
T
6
0
5
2
.
2
1
2
.
4
7
0
1
.
1
3
8
0
.
0
0
1
9
2
N
M
_
0
0
5
5
5
3
k
e
r
a
t
i
n
,
 
c
u
t
i
c
l
e
,
 
u
l
t
r
a
h
i
g
h
 
s
u
l
p
h
u
r
 
1
 
(
K
R
N
1
)
,
 
m
R
N
A
2
.
2
0
2
.
4
2
3
1
.
1
3
2
0
.
0
0
1
9
5
H
E
R
V
-
H
 
h
o
m
o
l
o
g
/
y
a
8
8
a
1
2
s
.
1
 
h
o
m
o
l
o
g
 
(
A
_
T
-
r
i
c
h
 
r
e
g
i
o
n
,
 
p
u
t
a
t
i
v
e
 
r
e
t
r
o
t
r
a
n
s
p
o
s
o
n
)
S
8
3
3
0
7
[
h
u
m
a
n
,
 
p
h
y
t
o
h
e
m
a
g
l
u
t
i
n
i
n
-
s
t
i
m
u
l
a
t
e
d
 
p
e
r
i
p
h
e
r
a
l
 
T
-
c
e
l
l
s
,
 
m
R
N
A
 
]
2
.
1
1
2
.
3
8
9
1
.
0
9
1
0
.
0
0
2
0
5
Y
1
6
7
0
1
m
R
N
A
 
f
r
o
m
 
H
I
V
 
a
s
s
o
c
i
a
t
e
d
 
n
o
n
-
H
o
d
g
k
i
n
'
s
 
l
y
m
p
h
o
m
a
 
(
c
l
o
n
e
 
h
l
1
-
7
2
)
2
.
0
6
2
.
3
8
7
1
.
0
3
9
0
.
0
0
1
9
9
A
F
1
2
4
8
1
9
T
8
4
 
c
o
l
o
n
 
c
a
r
c
i
n
o
m
a
 
c
e
l
l
 
I
L
-
1
b
e
t
a
 
r
e
g
u
l
a
t
e
d
 
H
S
C
C
1
 
m
R
N
A
2
.
2
9
2
.
3
7
4
1
.
1
6
6
0
.
0
0
2
0
5
N
M
_
0
1
4
3
8
7
l
i
n
k
e
r
 
f
o
r
 
a
c
t
i
v
a
t
i
o
n
 
o
f
 
T
 
c
e
l
l
s
 
(
L
A
T
)
,
 
m
R
N
A
1
.
7
8
2
.
3
2
3
0
.
8
2
9
0
.
0
0
1
9
0
N
M
_
0
0
5
1
1
0
g
l
u
t
a
m
i
n
e
-
f
r
u
c
t
o
s
e
-
6
-
p
h
o
s
p
h
a
t
e
 
t
r
a
n
s
a
m
i
n
a
s
e
 
2
 
(
G
F
P
T
2
)
 
m
R
N
A
1
.
7
0
2
.
2
5
2
0
.
7
6
7
0
.
0
0
1
8
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T
a
b
l
e
 
3
.
 
O
n
e
-
S
a
m
p
l
e
 
C
o
m
p
a
r
i
s
o
n
 
B
-
s
t
a
t
i
s
t
i
c
 
A
n
a
l
y
s
i
s
:
 
T
h
e
 
ﬁ
 
r
s
t
 
2
0
 
m
o
s
t
 
s
i
g
n
i
ﬁ
 
c
a
n
t
l
y
 
o
v
e
r
-
r
e
p
r
e
s
e
n
t
e
d
 
g
e
n
e
 
c
a
t
e
g
o
r
i
e
s
 
a
m
o
n
g
 
t
r
a
n
s
c
r
i
p
t
s
 
w
i
t
h
 
s
i
g
n
i
ﬁ
 
c
a
n
t
l
y
 
(
a
)
 
h
i
g
h
e
r
 
a
n
d
 
(
b
)
 
l
o
w
e
r
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
s
 
i
n
 
c
e
l
l
s
 
t
r
e
a
t
e
d
 
w
i
t
h
 
1
 
µ
M
 
c
i
s
p
l
a
t
i
n
.
 
T
h
e
 
n
u
m
b
e
r
 
o
f
 
t
r
a
n
s
c
r
i
p
t
s
 
i
n
 
e
a
c
h
 
g
e
n
e
 
c
a
t
e
g
o
r
y
 
(
L
i
s
t
 
H
i
t
s
)
 
i
s
 
a
l
s
o
 
p
r
e
s
e
n
t
e
d
 
a
s
 
a
 
p
e
r
c
e
n
t
a
g
e
 
o
f
 
a
l
l
 
t
h
e
 
t
r
a
n
s
c
r
i
p
t
s
 
b
e
l
o
n
g
i
n
g
 
t
o
 
t
h
a
t
 
c
a
t
e
g
o
r
y
 
t
h
a
t
 
w
e
r
e
 
a
c
t
u
a
l
l
y
 
p
r
e
s
e
n
t
 
o
n
 
t
h
e
 
m
i
c
r
o
a
r
r
a
y
 
(
P
o
p
u
l
a
t
i
o
n
 
H
i
t
s
)
.
 
G
e
n
e
 
c
a
t
e
g
o
r
i
e
s
 
d
e
n
o
t
e
d
 
w
i
t
h
 
a
n
 
a
s
t
e
r
i
s
k
 
w
e
r
e
 
a
l
s
o
 
s
i
g
n
i
ﬁ
 
c
a
n
t
l
y
 
o
v
e
r
-
r
e
p
r
e
s
e
n
t
e
d
 
a
m
o
n
g
 
t
r
a
n
s
c
r
i
p
t
s
 
d
e
m
o
n
s
t
r
a
t
i
n
g
 
t
h
e
 
s
a
m
e
 
e
x
p
r
e
s
s
i
o
n
 
r
e
s
p
o
n
s
e
 
i
n
 
t
r
a
n
s
p
l
a
-
t
i
n
 
t
r
e
a
t
e
d
 
c
e
l
l
s
.
R
a
n
k
G
O
 
s
y
s
t
e
m
G
e
n
e
 
c
a
t
e
g
o
r
y
L
i
s
t
 
h
i
t
s
P
o
p
u
l
a
t
i
o
n
 
h
i
t
s
%
 
P
o
p
u
l
a
t
i
o
n
 
h
i
t
s
E
A
S
E
 
s
c
o
r
e
(
a
)
 
G
e
n
e
 
c
a
t
e
g
o
r
i
e
s
 
o
v
e
r
-
r
e
p
r
e
s
e
n
t
e
d
 
a
m
o
n
g
 
u
p
-
r
e
g
u
l
a
t
e
d
 
t
r
a
n
s
c
r
i
p
t
s
1
B
i
o
l
o
g
i
c
a
l
 
P
r
o
c
e
s
s
l
i
p
i
d
 
m
e
t
a
b
o
l
i
s
m
 
*
1
0
0
4
7
4
2
1
1
.
7
9
 
×
 
1
0
-
1
9
2
B
i
o
l
o
g
i
c
a
l
 
P
r
o
c
e
s
s
t
r
a
n
s
p
o
r
t
 
*
2
1
0
1
6
4
6
1
3
8
.
2
3
 
×
 
1
0
-
1
3
3
B
i
o
l
o
g
i
c
a
l
 
P
r
o
c
e
s
s
m
e
m
b
r
a
n
e
 
l
i
p
i
d
 
m
e
t
a
b
o
l
i
s
m
 
*
2
7
9
3
2
9
1
.
0
5
 
×
 
1
0
-
0
8
4
B
i
o
l
o
g
i
c
a
l
 
P
r
o
c
e
s
s
p
h
o
s
p
h
o
l
i
p
i
d
 
m
e
t
a
b
o
l
i
s
m
 
*
2
1
5
9
3
6
1
.
4
4
 
×
 
1
0
-
0
8
5
B
i
o
l
o
g
i
c
a
l
 
P
r
o
c
e
s
s
l
i
p
i
d
 
b
i
o
s
y
n
t
h
e
s
i
s
 
*
3
6
1
6
4
2
2
6
.
9
3
 
×
 
1
0
-
0
8
6
M
o
l
e
c
u
l
a
r
 
F
u
n
c
t
i
o
n
t
r
a
n
s
p
o
r
t
e
r
 
a
c
t
i
v
i
t
y
 
*
1
7
8
1
5
4
2
1
2
1
.
2
9
 
×
 
1
0
-
0
7
7
M
o
l
e
c
u
l
a
r
 
F
u
n
c
t
i
o
n
p
o
r
t
e
r
 
a
c
t
i
v
i
t
y
 
*
3
7
1
8
4
2
0
3
.
7
7
 
×
 
1
0
-
0
7
8
M
o
l
e
c
u
l
a
r
 
F
u
n
c
t
i
o
n
e
l
e
c
t
r
o
c
h
e
m
i
c
a
l
 
p
o
t
e
n
t
i
a
l
-
d
r
i
v
e
n
 
t
r
a
n
s
p
o
r
t
e
r
 
a
c
t
i
v
i
t
y
 
*
3
7
1
8
5
2
0
4
.
3
3
 
×
 
1
0
-
0
7
9
B
i
o
l
o
g
i
c
a
l
 
P
r
o
c
e
s
s
p
h
o
s
p
h
o
l
i
p
i
d
 
b
i
o
s
y
n
t
h
e
s
i
s
 
*
1
4
3
3
4
2
6
.
8
6
 
×
 
1
0
-
0
7
1
0
M
o
l
e
c
u
l
a
r
 
F
u
n
c
t
i
o
n
d
y
n
e
i
n
 
A
T
P
a
s
e
 
a
c
t
i
v
i
t
y
 
*
9
1
4
6
4
3
.
1
5
 
×
 
1
0
-
0
6
1
1
M
o
l
e
c
u
l
a
r
 
F
u
n
c
t
i
o
n
c
a
r
r
i
e
r
 
a
c
t
i
v
i
t
y
 
*
6
0
4
0
6
1
5
4
.
4
0
 
×
 
1
0
-
0
6
1
2
B
i
o
l
o
g
i
c
a
l
 
P
r
o
c
e
s
s
l
i
p
i
d
 
t
r
a
n
s
p
o
r
t
 
*
1
6
5
4
3
0
1
.
5
0
 
×
 
1
0
-
0
5
1
3
C
e
l
l
u
l
a
r
 
C
o
m
p
o
n
e
n
t
i
n
t
e
r
m
e
d
i
a
t
e
 
ﬁ
 
l
a
m
e
n
t
 
c
y
t
o
s
k
e
l
e
t
o
n
 
*
1
8
6
9
2
6
1
.
8
1
 
×
 
1
0
-
0
5
1
4
B
i
o
l
o
g
i
c
a
l
 
P
r
o
c
e
s
s
m
e
m
b
r
a
n
e
 
l
i
p
i
d
 
b
i
o
s
y
n
t
h
e
s
i
s
 
*
1
4
4
3
3
3
2
.
0
5
 
×
 
1
0
-
0
5
1
5
M
o
l
e
c
u
l
a
r
 
F
u
n
c
t
i
o
n
m
o
t
o
r
 
a
c
t
i
v
i
t
y
 
*
2
4
1
1
2
2
1
2
.
1
0
 
×
 
1
0
-
0
5
1
6
M
o
l
e
c
u
l
a
r
 
F
u
n
c
t
i
o
n
m
i
c
r
o
t
u
b
u
l
e
 
m
o
t
o
r
 
a
c
t
i
v
i
t
y
 
*
1
4
4
4
3
2
2
.
5
1
 
×
 
1
0
-
0
5
1
7
M
o
l
e
c
u
l
a
r
 
F
u
n
c
t
i
o
n
l
i
p
i
d
 
t
r
a
n
s
p
o
r
t
e
r
 
a
c
t
i
v
i
t
y
 
*
1
6
5
8
2
8
3
.
5
2
 
×
 
1
0
-
0
5
1
8
B
i
o
l
o
g
i
c
a
l
 
P
r
o
c
e
s
s
a
l
c
o
h
o
l
 
m
e
t
a
b
o
l
i
s
m
 
*
3
5
2
1
1
1
7
0
.
0
0
0
0
7
1
9
B
i
o
l
o
g
i
c
a
l
 
P
r
o
c
e
s
s
e
n
d
o
c
y
t
o
s
i
s
 
*
2
2
1
0
7
2
1
0
.
0
0
0
1
0
2
0
B
i
o
l
o
g
i
c
a
l
 
P
r
o
c
e
s
s
s
t
e
r
o
i
d
 
m
e
t
a
b
o
l
i
s
m
 
*
2
2
1
0
9
2
0
0
.
0
0
0
1
4
(
b
)
 
G
e
n
e
 
c
a
t
e
g
o
r
i
e
s
 
o
v
e
r
-
r
e
p
r
e
s
e
n
t
e
d
 
a
m
o
n
g
 
d
o
w
n
-
r
e
g
u
l
a
t
e
d
 
t
r
a
n
s
c
r
i
p
t
s
1
M
o
l
e
c
u
l
a
r
 
F
u
n
c
t
i
o
n
s
i
g
n
a
l
 
t
r
a
n
s
d
u
c
e
r
 
a
c
t
i
v
i
t
y
 
*
3
2
1
9
0
1
1
.
7
0
.
0
0
0
6
2
M
o
l
e
c
u
l
a
r
 
F
u
n
c
t
i
o
n
s
u
g
a
r
 
b
i
n
d
i
n
g
 
*
6
9
9
6
.
1
0
.
0
0
2
1
3
M
o
l
e
c
u
l
a
r
 
F
u
n
c
t
i
o
n
r
e
c
e
p
t
o
r
 
a
c
t
i
v
i
t
y
 
*
2
1
1
1
6
3
1
.
8
0
.
0
0
3
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4
B
i
o
l
o
g
i
c
a
l
 
P
r
o
c
e
s
s
c
e
l
l
 
s
u
r
f
a
c
e
 
r
e
c
e
p
t
o
r
 
l
i
n
k
e
d
 
s
i
g
n
a
l
 
t
r
a
n
s
d
u
c
t
i
o
n
 
*
1
9
9
6
8
2
.
0
0
.
0
0
4
7
5
M
o
l
e
c
u
l
a
r
 
F
u
n
c
t
i
o
n
t
r
a
n
s
m
e
m
b
r
a
n
e
 
r
e
c
e
p
t
o
r
 
a
c
t
i
v
i
t
y
 
*
1
4
7
5
6
1
.
9
0
.
0
1
9
5
6
B
i
o
l
o
g
i
c
a
l
 
P
r
o
c
e
s
s
r
e
s
p
o
n
s
e
 
t
o
 
a
b
i
o
t
i
c
 
s
t
i
m
u
l
u
s
 
*
1
1
4
9
4
2
.
2
0
.
0
2
0
2
7
B
i
o
l
o
g
i
c
a
l
 
P
r
o
c
e
s
s
d
e
v
e
l
o
p
m
e
n
t
 
*
2
5
1
6
4
6
1
.
5
0
.
0
2
1
5
8
B
i
o
l
o
g
i
c
a
l
 
P
r
o
c
e
s
s
c
e
l
l
 
c
o
m
m
u
n
i
c
a
t
i
o
n
 
*
3
7
2
7
4
4
1
.
3
0
.
0
2
1
6
9
C
e
l
l
u
l
a
r
 
C
o
m
p
o
n
e
n
t
m
e
m
b
r
a
n
e
 
*
4
8
4
0
3
9
1
.
2
0
.
0
3
2
1
1
0
B
i
o
l
o
g
i
c
a
l
 
P
r
o
c
e
s
s
n
e
u
r
o
p
e
p
t
i
d
e
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expression changes were only approximately 
two-fold relative to control (non-treated) samples 
(see Table 1). Since a key aim of this work was to 
study treatment-speciﬁ  c gene expression events, 
an alternative method for comparing the transcrip-
tional responses to each treatment was investigated. 
For this purpose, a two-sample comparison B-sta-
tistic analysis was employed to contrast the ‘control 
vs treatment’ proﬁ  les already established for cis-
platin and transplatin.
Two-sample comparison B-statistic 
analysis
The two-sample B-statistic analysis facilitated the 
simultaneous comparison of microarray data from 
two different ‘control vs treatment’ experiments. 
Through the inter-array comparison of samples 
labelled with the same dye, B-statistics were used 
to detect more subtle differences in the expression 
responses to cisplatin and transplatin exposure, 
without the interference of dye biases. This 
approach, however, failed to recognise any consis-
tently signiﬁ  cant differences between the expres-
sion proﬁ  les induced by 5 hour 1 µM cisplatin and 
transplatin treatments. This implied a very high 
degree of similarity between the transcriptional 
responses of ﬁ  broblasts to these equimolar doses 
of cisplatin and transplatin. In contrast, two-sample 
comparison B-statistics readily detected signiﬁ  cant 
differences between the responses to 1 µM cispla-
tin and 25 µM transplatin treatments. Altogether, 
105 transcripts were found to be signiﬁ  cantly more 
abundant in the 1 mM cisplatin treatments while 
64 transcripts were more abundant in the 25 µM 
transplatin treatments (Table 1). For many of these 
genes, the origin or cause of their differential 
response could be clariﬁ  ed by cross-comparing the 
results of the two-sample comparisons with those 
of the one-sample comparisons. For example, 
transcripts that were more abundant in cisplatin 
treatments could be further classiﬁ  ed as being 
‘actively up-regulated by cisplatin’ if they were 
also present among the up-regulated genes of the 
one-sample ‘control vs 1 µM cisplatin’ compari-
sons. An overview of this classiﬁ  cation process is 
presented in Figure 4. Of the 105 transcripts more 
abundant in cisplatin treatments, 27 were classiﬁ  ed 
as being up-regulated by cisplatin (Table 4), 35 as 
being down-regulated by transplatin (Table 5), and 
43 could not be classiﬁ  ed into either group using 
the current one-sample data (Table 6). Of the 
64 transcripts more abundant in transplatin 
treatments, 12 were classed as being up-regulated 
by transplatin (Table 7), 19 as being down-regu-
lated by cisplatin (Table 8), and 33 did not correlate 
with any one-sample comparisons (Table 9).
Functions within EASE were also employed to 
detect gene categories that were signiﬁ  cantly over-
represented among the 169 transcripts differen-
tially expressed between cisplatin and transplatin 
treatments. Tables 10 and 11 show some of the 
most over-represented categories among transcripts 
found to be more abundant in 1 µM cisplatin and 
25 µM transplatin treatments, respectively.
Discussion
The effect of the anti-tumour drug, cisplatin, on 
human gene expression was investigated using 
microarray-based transcription proﬁ  ling techniques 
in human cells. The transcriptional response of 
human ﬁ  broblasts to a clinically relevant cisplatin 
dose was examined in detail using human 19K 
microarrays. Gene expression proﬁ  les were also 
compiled for transplatin, the therapeutically inef-
fective isomer of cisplatin. Statistically robust 
methods for assessing the signiﬁ  cance of apparent 
changes in gene expression were then investigated. 
The ﬁ  rst approach permitted the identiﬁ  cation of 
human gene transcripts exhibiting signiﬁ  cantly 
different expression levels in drug-treated com-
pared to control samples. A second method was 
then used to reveal transcripts that were differen-
tially expressed between the three drug treatments 
examined. During these comparisons, a subset of 
169 transcripts was found to be differentially 
expressed between cisplatin and transplatin treat-
ments. Gene ontology databases were used to 
recognise gene categories that were comparatively 
over-represented among the signiﬁ  cant transcripts, 
compared to what was represented on the microar-
rays. This allowed the biological themes of the 
differential responses to cisplatin and transplatin 
treatments to be explored and further considered 
with respect to anti-tumour activity.
Transcription proﬁ  ling in drug-treated 
cells: overview
Toxic stress in cells can stimulate a range of 
biological responses, including the transcriptional 
modulation of genes regulating cell survival, DNA 
repair and cell death. It has thus been proposed 
that such complex patterns of induced gene 329
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expression changes could provide considerable 
insight into the mechanism of action of various 
toxic agents (Amin et al. 2002; Amundson et al. 
1999; Caba et al. 2005; Hamadeh et al. 2002; 
Newton et al. 2004). For example, the discipline 
of toxicogenomics seeks to exploit the complexity 
of this response for the purpose of generating a 
molecular proﬁ  le or signature that is characteristic 
of speciﬁ  c toxicant exposure (reviewed by (Gant 
and Zhang, 2005)). Furthermore, microarray-
based genomic approaches can now serve as a 
powerful tool for exploring the molecular 
pathways and cellular processes that mediate the 
adverse responses to a particular compound (Caba 
et al. 2005).
The broad aim of the microarray experiments 
conducted in the present study was to investigate 
global gene expression responses to cisplatin expo-
sure in human cells. The ﬁ  rst signiﬁ  cant outcome 
of this project was the establishment of distinct 
gene expression proﬁ  les for equitoxic doses of 
cisplatin and transplatin, relative to solvent (DMF) 
controls.
The second and somewhat more challenging 
aim of this study was to identify gene expression 
events that are unique to cisplatin treatment and 
Two-sample B-statistic Analysis
DMF vs 1 µM cisplatin DMF vs 25 µM transplatin vs
105 Transcripts more abundant in 
1 µM cisplatin 
treatments
64 Transcripts more abundant in 
25 µM transplatin
treatments
Transcripts
UP-regulated by 
1 µM cisplatin
Table 4
Transcripts
DOWN-regulated by 
25 µM transplatin
Table 5
Transcripts
UP-regulated by 
25 µM transplatin
Table 7
Transcripts
DOWN-regulated by 
1 µM cisplatin
Table 8
43 Transcripts
for which the origin of 
differential expression 
could not be 
determined
Table 6
33 Transcripts
for which the origin of 
differential expression 
could not be 
determined
Table 9
1 µM cisplatin  25 µM transplatin
27 35 19 12
Figure 4. Overview of the two-sample comparison B-statistic analysis. This approach facilitated the simultaneous comparison of data 
from ‘DMF (control) vs 1 µM cisplatin’ and ‘DMF (control) vs 25 µM transplatin’ microarray comparisons. Through the inter-array comparison 
of treatments labelled with the same dye, B-statistics were used to detect subtle differences in the expression responses to cisplatin and 
transplatin without the interference of dye biases. During this analysis, 105 transcripts were found to be signiﬁ  cantly more abundant in the 
1 µM cisplatin treatments while 64 transcripts were more abundant in the 25 µM transplatin treatments. The origin or cause of these differ-
ential expression events was then clariﬁ  ed by cross-comparing two-sample comparison results with those of the one-sample comparisons. 
Positive correlations then allowed signiﬁ  cant transcripts to be classiﬁ  ed as being actively up-regulated by cisplatin, down-regulated by 
transplatin, upregulated by transplatin or down-regulated by cisplatin. Other signiﬁ  cant transcripts could not be classiﬁ  ed into one of the four 
categories above, due to the absence of corresponding one-sample comparison data.330
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p
l
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p
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r
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c
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p
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l
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could play an important role in its cytotoxic 
mechanism. For this purpose, transcription proﬁ  les 
constructed for cisplatin and its clinically ineffec-
tive isomer, transplatin, were compared. Many 
toxic compounds will lead to the induction of genes 
that are unrelated to anti-tumour activity. However, 
the use of active and inactive anti-tumour agents 
permits the identiﬁ  cation of responses that contrib-
ute to anti-tumour activity and responses that do 
not contribute to anti-tumour activity. When suf-
ﬁ  cient data from different agents is combined, as 
in the case with cisplatin and transplatin, it may be 
possible to differentiate generic stress responses 
from compound-speciﬁ  c events (Burczynski et al. 
2000; Gant and Zhang, 2005).
In order to extract accurate and informative data 
from this kind of gene expression study, there are 
several major experimental considerations that must 
also be addressed. One particular concern surrounds 
the biological system employed and its associated 
variables. In this project, non-transformed human 
foreskin ﬁ  broblasts were chosen as the initial cell 
type in which drug-induced gene expression proﬁ  les 
would be monitored. Most gene expression studies 
with cisplatin have been focused upon cancer cells 
against which cisplatin is successfully cytotoxic 
or ineffective due to problems of resistance (Clarke 
et al. 2004; Huerta et al. 2003; Lee et al. 2005; 
Macleod et al. 2005; Nakatani et al. 2005; Roberts 
et al. 2005; Takata et al. 2005; Toshimitsu et al. 
2004; Wilson et al. 2005). Since both cancer and 
non-cancer cells of a patient are exposed to clinical 
treatments, a detailed look at the response of ‘nor-
mal’ cells to cisplatin may provide a more balanced 
insight into the toxic mechanism of this drug. Also, 
a number of important genes are “inactivated” in 
many tumour cells, such as p53 and retinoblastoma 
(Hill et al. 2005; Levine and Fleischli, 2000; Miller 
et al. 1996; Scheffner et al. 1991; Vaziri and 
Benchimol, 1999). Insight into the effect of cis-
platin on the functional versions of such genes 
might thus be gained via the use of non-cancer cells 
in gene expression studies.
Biological variables that arise from experimen-
tal design, such as dose and time of exposure to 
the compound, also have a large impact on the 
analysis and subsequent interpretation of microar-
ray data. These factors were thus given thorough 
consideration in the current study via several pre-
liminary experiments. Filter macroarray studies 
revealed signiﬁ  cant changes in gene expression 
upon the treatment of cells with 5 hour doses of 
X
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8 cisplatin at concentrations between 1 and 50 µM. 
This study focused upon a moderate set of treat-
ment conditions and a concentration of 1 µM 
cisplatin was chosen, since this dose falls within 
clinical ranges and has also been used in other 
microarray-based gene expression studies with 
cisplatin (Higuchi et al. 2003). Furthermore, this 
dose was not found to induce high levels of cell 
death in ﬁ  broblasts, according to cytotoxicity assay 
results. While gene expression profiles have 
already been used to deﬁ  ne toxicity in various 
biological systems (Chang et al. 2003; Gant, 2002; 
van 't Veer et al. 2002), many of the chemical 
agents have been used at signiﬁ  cantly toxic levels. 
It is now being recognised that more biologically 
relevant results are obtained under conditions of 
mild toxicity, particularly in the absence of any 
cellular or pathological changes (Gant and Zhang, 
2005). Moreover, this approach has been success-
fully applied to identify differentially expressed 
genes during inﬂ  ammatory responses to hexachlo-
robenzene (Ezendam et al. 2004). Together, these 
observations lend further support for the ﬁ  nal 
choice of treatment conditions investigated here.
In order to compare the differential effects of 
cisplatin and transplatin treatments, two different 
concentrations of the clinically ineffective isomer 
were examined. In addition to an equimolar dose 
of 1 µM, a second approximately equitoxic dose 
of 25 µM transplatin was also selected for com-
parison with 1 µM cisplatin. Similar investigations 
have required transplatin at various doses between 
2 and 100 times the concentration of cisplatin to 
achieve equitoxic effects (Burczynski et al. 2000; 
Sanchez-Perez et al. 1998; Sato et al. 1996). In 
addition, at least four-fold more transplatin than 
cisplatin adducts have been required to signiﬁ  -
cantly inhibit transcription elongation in HeLa cells 
(Mello et al. 1995). However, in comparing 1 µM 
cisplatin and 25 µM transplatin doses, it is also 
possible that observed differences between gene 
expression proﬁ  les may arise purely due to the 
difference in drug ‘loads’. While the cytotoxicity 
assay indicated that relative toxicity levels were 
the same for these two treatments, the possibility 
of dose effects should also be taken into consider-
ation. Interestingly, in the ﬁ  nal microarray data, 
the relative magnitude of gene expression changes 
in 1 µM cisplatin-treated cells was generally more 
similar to the magnitude of changes in 25 µM 
transplatin treatments than in 1 µM transplatin 344
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treatments. This observation supports the ﬁ  nal 
choice of isomer doses for comparison.
Apart from biological variables, another major 
experimental challenge relates to the intrinsic dif-
ﬁ  culties associated with the accurate measurement 
of gene expression – a problem that is further 
enlarged by the number of genes on a microarray. 
A means of overcoming such technical variations 
is through correct experimental design and the 
implementation of analytical procedures that 
ensure the data is as free from systematic errors as 
possible (Gant and Zhang, 2005; Zhang and Gant, 
2004). In the current study, these issues were pri-
marily addressed within the preliminary investiga-
tions. Microarray experiments using slides with 
smaller gene-sets were employed to trial hybridi-
sation and array-scanning techniques with ﬂ  uores-
cent dyes. Also, these trials used cDNA samples 
derived from HeLa and K562 cancer cells, since 
these cell lines were well characterised and known 
to be stable. Subsequent experiments conducted 
with larger arrays compared control (DMF) and 
cisplatin-treated samples in order to ascertain 
whether a stable response to the anti-tumour drug 
could be detected. As expected, the magnitude of 
the differences in gene expression levels between 
control and treated samples was signiﬁ  cantly lower 
than that observed between the proﬁ  les of the two 
different cell lines. However, the fact that a subset 
of genes was found to exhibit signiﬁ  cantly differ-
ent expression levels in response to drug treatment 
satisﬁ  ed a major goal of this project, which was to 
establish a gene expression proﬁ  le for cisplatin-
treated human cells using microarray technology.
The ultimate aim of this work then became to 
develop a complete system for reliably determining 
differentially expressed genes in drug-treated cells. 
In future research, such a test system could then 
be used with conﬁ  dence to investigate the cytotoxic 
potential of other compounds (Burczynski et al. 
2000; Caba et al. 2005; Gant and Zhang, 2005).
Oligonucleotide microarrays were used to inves-
tigate the transcriptional response of human ﬁ  bro-
blasts to drug treatment. Through the use of reﬁ  ned 
normalisation procedures and rigorous statistical 
evaluation techniques, these experiments produced 
ﬁ  nite sets of genes that were classed as being dif-
ferentially expressed in response to each of the three 
treatments examined. Additional cross-comparisons 
between different data sets led to the identiﬁ  cation 
of a subset of genes that were differentially expressed 
between cisplatin and transplatin treatments.
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The following sections briefly review and 
integrate the relevant literature relating to some of 
the more signiﬁ  cant biological outcomes of the 
fibroblast microarray experiments. Particular 
emphasis is placed on the transcripts found to be 
differentially expressed between similarly toxic 
doses of cisplatin and transplatin. Since very rigor-
ous and statistically robust methods for assessing 
differential gene expression were implemented in 
this part of the analysis, many of these transcripts 
are considered to be very good candidates for fur-
ther investigation.
Transcriptional responses common 
to cisplatin and transplatin treatments
The most important function of the one-sample 
B-statistic analyses was to identify genes with 
signiﬁ  cantly different expression levels in control 
and drug-treated ﬁ  broblast samples. For all three 
treatments examined, results from the one-sample 
comparisons of microarray data clearly indicated 
that the cells exhibited a distinct transcriptional 
response to drug treatment (relative to control).
Differentially expressed transcripts were 
detected for each of the three treatments, forming 
separate transcription proﬁ  les for 1 µM cisplatin, 
1 µM transplatin and 25 µM transplatin. Many of 
the differentially expressed transcripts were com-
mon to all three treatment profiles. However, 
considering the structural similarities between the 
two compounds and the relatively narrow dose 
range examined, this observation was not unex-
pected. A similar study by Burczynski and col-
leagues also describes a number of differentially 
expressed genes that are common to transcription 
proﬁ  les compiled for equitoxic doses of cisplatin 
and transplatin (Burczynski et al. 2000). Although 
it was not the purpose of this investigation to anal-
yse these proﬁ  les in detail, it was interesting to 
note that some of the expression responses corre-
lated well with observations from other DNA 
damage studies. For example, the interferon regu-
latory factors, IRF3 and IRF6, were both distinctly 
up-regulated in response to cisplatin and transpla-
tin exposure in this study. The products of these 
genes are involved in a wide range of host defense 
mechanisms, and their activation by various envi-
ronmental stresses, including DNA damage, has 
been well documented (Kim et al. 1999; Missiaglia 
et al. 2005). In the case of down-regulated tran-
scripts, glutathione peroxidase 1 (GPX1) 
demonstrated signiﬁ  cantly reduced expression 
levels in the cisplatin and transplatin treatments 
examined here. Similarly, decreased glutathione 
peroxidase expression and activity levels have 
already been observed following cisplatin exposure 
in a range of biological systems (Huang et al. 1997; 
Khynriam and Prasad, 2002; Naziroglu et al. 2004; 
Saad et al. 2004). Overall, such correlations clearly 
support the results obtained in this study.
EASE software was used to determine gene 
categories that were signiﬁ  cantly over-represented 
among the transcripts of each treatment proﬁ  le (see 
Table 3). Similarities between these expression 
proﬁ  les meant that many of the over-represented 
gene categories were also common to the three 
treatment groups. A number of the commonly over-
represented categories corresponded to functions 
that have been previously implicated in the cel-
lular response to toxic insult. Some of these 
involved genes with established roles in biological 
processes such as transport, cell growth and/or 
maintenance, signal transduction, cell proliferation 
and regulation of cell cycle. Other signiﬁ  cant 
groups, such as lipid metabolism (which was the 
most over-represented category among up-
regulated genes, see Table 3), have only few or no 
former associations with the cellular response to 
DNA damage (Vetoshkina and Dubskaia, 1993). 
Transcripts with roles in lipid metabolism included 
retinol dehydrogenase 16 (RODH-4), alkylglyce-
rone phosphate synthase (AGPS) and apolipopro-
tein C-III (APOC3). Indeed, the complex series of 
events that results from drug-induced DNA damage 
involves multiple biological pathways, many of 
which are yet to be deﬁ  ned. Therefore, some of the 
signiﬁ  cant genes identiﬁ  ed here could prove to be 
novel regulators or mediators within the signal 
transduction pathways that are stimulated by DNA-
adduct formation. Other transcripts may simply be 
part of the broader ﬁ  broblast response to toxic 
insult.
The next major goal of this investigation was 
to identify treatment-specific gene expression 
responses. While the microarray experiments that 
directly compared 1 µM cisplatin with 1 µM or 25 
µM transplatin were originally designed to identify 
transcripts that were differentially expressed 
between treatments, one-sample B-statistic analy-
ses failed to accurately reveal any such genes. It is 
most likely that systematic errors and biases in the 
microarray data signiﬁ  cantly contributed to this 
outcome. However, as an alternative approach, 347
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two-sample B-statistic analyses were employed to 
facilitate the indirect comparison of expression 
proﬁ  les determined for the three ‘control vs treat-
ment’ comparisons. Since these ‘treatment’ samples 
were all labelled with the same ﬂ  uorescent dye 
(Cy3), this technique strongly reduced the likelihood 
of false positive results and dye-speciﬁ  c biases in 
the data. By implementing strict inclusion criteria 
and a robust deﬁ  nition for differential expression, 
the ﬁ  nal outcome was a concise list of transcripts 
that were found to exhibit signiﬁ  cantly different 
expression levels in cisplatin- and transplatin-treated 
ﬁ  broblasts.
Gene expression proﬁ  les unique to 
cisplatin and transplatin treatments
The two-sample comparison approach for inter-
array data analysis readily identiﬁ  ed transcripts that 
were differentially expressed between cisplatin 
and transplatin treatments. Altogether, 105 tran-
scripts were found to be significantly more 
abundant in cisplatin treatments (Tables 4–6), 
while 64 transcripts were expressed to a greater 
extent in transplatin treatments (Tables 7–9). The 
application of gene ontology (GO) mapping and 
pathway analysis to this data illustrated the way in 
which such gene expression events could be placed 
in the context of the underlying pathways and 
processes affected. Among the 169 signiﬁ  cant 
transcripts, EASE revealed a number of distinct 
and sometimes opposing biological themes. 
A particularly interesting result was ‘negative 
regulation of cell proliferation’, which was one of 
the more dominant themes associated with cispla-
tin treatments (Table 10). Genes assigned to this 
category included IL6, IL1B, IL8, TGFB1, GAS1, 
and ETS1. Other over-represented gene categories 
that reﬂ  ected cisplatin’s negative effects on cell 
growth were ‘apoptosis’, ‘programmed cell death’ 
and ‘cell cycle arrest’. Together, these themes are 
consistent with cisplatin’s effective cytotoxic 
mechanism.
In sharp contrast, EASE characterised transpl-
atin’s differential transcript proﬁ  le with a signiﬁ  -
cant proportion of genes involved in the ‘positive 
regulation of cell proliferation’ (Table 11). These 
included DTR, CUL3 and IRS2. Other subsets of 
genes abundant in transplatin treatments had estab-
lished roles in a range of more general nucleic acid 
metabolism and processing functions. Among 
these, RNA/mRNA binding and splicing properties 
were common, and ‘regulation of DNA-dependent 
transcription’ was represented by at least eight 
genes. Broadly, these themes suggest that cellular 
activities following transplatin exposure are 
focused at the level of DNA/RNA interactions and 
various transcriptional processes. Together with 
the ‘positive regulation of cell proliferation’ gene 
group, this could partly indicate the early effort or 
ability of cells to overcome the interference of 
transplatin adducts and maintain normal cellular 
processes.
Other aspects of transplatin’s differential tran-
script proﬁ  le related to methods for circumventing 
the negative effects of platinum exposure. For 
example, several transcripts more abundant in 
transplatin treatments mapped to ‘heavy metal 
sensitivity/resistance’, ‘metal ion homeostasis’ and 
transport-related categories. This suggests that 
under the conditions employed here, some detox-
iﬁ  cation pathways may be more active in response 
to transplatin than to cisplatin. Some of these genes 
may play a role in processes that act to lower intra-
cellular transplatin concentrations and thus help to 
prevent any drug-mediated interference with nor-
mal cell growth.
This interpretation would also be consistent 
with transplatin’s status as the therapeutically inac-
tive isomer.
In contrast, many of the dominating biological 
processes and molecular functions associated with 
cisplatin’s differential expression proﬁ  le were 
directly concerned with the immediate fate of a 
cell (Table 10). ‘Regulation of cell proliferation’, 
‘cell cycle arrest’ and ‘apoptosis’ are prime exam-
ples of such crucial processes. Interestingly, these 
categories were not as signiﬁ  cantly represented 
among the transcripts of transplatin’s unique pro-
ﬁ  le. However, since both adduct recognition and 
repair processes can differ signiﬁ  cantly for damage 
induced by cisplatin and transplatin, this observa-
tion may reﬂ  ect the early differential response of 
cells to the two isomers (Ciccarelli et al. 1985; 
Hansson and Wood, 1989; Heiger-Bernays et al. 
1990; Huang et al. 1994; Jamieson and Lippard, 
1999; McA’Nulty and Lippard, 1996; Mello et al. 
1995; Zamble et al. 1996). Also, while cisplatin 
and transplatin have been shown to inhibit DNA 
synthesis in a similar manner (Bernges and Holler, 
1988; Ciccarelli et al. 1985; Harder et al. 1976; 
Heiger-Bernays et al. 1990; Mello et al. 1995; 
Salles et al. 1983), their differential effects on 
RNA transcription are also widely acknowledged 348
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(Brabec and Leng, 1993; Corda et al. 1993; Evans 
and Gralla, 1992; Mello et al. 1995; Mymryk et al. 
1995; Zlatanova et al. 1998). Thus, it seems likely 
that transcript proﬁ  les would also reﬂ  ect such 
differences.
Overall, the results described here suggest that, 
even at low doses, cisplatin may elicit a more 
complex stress response in cells compared to trans-
platin. This might then imply that the need to 
determine the immediate fate of a cell is more 
urgent in response to cisplatin exposure. Support-
ing this notion was the abundance of transcripts 
pertaining to the immune system, communication 
and cell signalling processes in cisplatin treat-
ments. In an attempt to further characterise the 
molecular events that may be associated with the 
anti-tumour activity of cisplatin, some of the genes 
found to be speciﬁ  cally regulated by cisplatin 
(Tables 4 and 8), were considered in more detail.
Inter-array two-sample B-statistic comparisons 
effectively revealed at least 169 transcripts that 
were differentially expressed between cisplatin and 
transplatin treatments. The incorporation of results 
from the one-sample ‘control vs treatment’ com-
parisons provided a means to clarify the origins of 
a subset of these differential responses. These 
subsets, presented in Tables 4, 5, 7 and 8, describe 
the more consistent and statistically signiﬁ  cant 
transcriptional responses that were differentially 
elicited by cisplatin and transplatin in this study. 
A brief functional review of some of the better 
characterised genes that were specifically up- 
(Table 4) or down-regulated (Table 8) by cisplatin 
gave insight into some of the processes that may 
contribute towards the anti-tumour activity of this 
compound.
Genes speciﬁ  cally up-regulated 
in response to cisplatin
The most common biological themes among the 
transcripts up-regulated by cisplatin involved 
cytokines, the regulation of cell proliferation, and 
other aspects of the cellular immune/defense 
response. Classed within each of these categories 
were the cytokines IL-1B, IL-6 and IL-8, which 
were all consistently up-regulated in response to 
cisplatin treatments. These molecules are important 
mediators of the inﬂ  ammatory response and are 
also involved in a diverse range of cellular activities 
such as cell proliferation, differentiation, angio-
genesis and apoptosis. Their ability to exert direct 
cytotoxic effects on tumour cells (Gaffney and Tsai, 
1986; Poppenborg et al. 1999) or potentiate the 
effects of certain anti-tumour agents, has also been 
demonstrated (Benchekroun et al. 1993). There-
fore, the collective increase in cytokine transcripts 
observed in the cisplatin-speciﬁ  c expression proﬁ  le 
was considered to be signiﬁ  cant. Several studies 
have already demonstrated a signiﬁ  cant rise in 
interleukin-1 levels after cisplatin treatments in 
cultured cells (Shi et al. 1998; Sodhi and Pai, 1992; 
Suresh and Sodhi, 1991; Toubi et al. 2003) and in 
patients undergoing chemotherapy (Baiocchi et al. 
1993). Furthermore, other groups have speciﬁ  cally 
reported that IL-1 enhances the sensitivity of 
tumour cells to cisplatin and that synergistic inter-
actions between IL-1 and cisplatin may actually 
enhance p53-dependent apoptosis (Benchekroun 
et al. 1993; Poppenborg et al. 1999; Song et al. 
1998).
The behaviour of cytokines IL-6 and IL-8 has 
also been examined extensively, particularly in 
cancer patients (Baiocchi et al. 1993; Bhalla et al. 
2000; Darai et al. 2003). As for IL-1, an increased 
production of IL-6 and IL-8 in response to cispla-
tin has also been observed (Baiocchi et al. 1993; 
Shi et al. 1998; Toubi et al. 2003). In this study, 
the cisplatin-induced increase in IL-1B, IL-6 and 
IL-8 expression is thus consistent with previous 
ﬁ  ndings and with the role of these cytokines as key 
biochemical modulators in a range of important 
biological functions.
Other elements of cisplatin’s unique transcript 
proﬁ  le relate to important signalling events that 
can affect DNA synthesis and cellular proliferation. 
For example, NMB, ITPR3 and PRKCBP1 are all 
implicated in the phosphoinositide cascade, which 
involves the activation of protein kinase C (PKC) 
and subsequent PKC-mediated effects. In this 
study, these three genes were specifically up-
regulated in response to cisplatin exposure 
(Table 4). Neuromedin B (NMB) is a bombesin-
like peptide found chieﬂ  y in the central nervous 
system and gastrointestinal tract (Minamino et al. 
1983; Minamino et al. 1985; Namba et al. 1985). 
This peptide demonstrates autocrine and paracrine 
growth factor activity in some carcinomas (Lach 
et al. 1995; Moody et al. 1992; Mukai et al. 1987; 
Otsuki et al. 1987), but in its role as a bifunctional 
regulator of cell growth, it can also signiﬁ  cantly 
inhibit cell growth when at high levels (Dobrzan-
ski et al. 1993). ITPR3 and PRKCBP1 have other 
roles in the PKC transduction pathway. ITPR3 is 349
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a second messenger receptor that acts as an intra-
cellular calcium channel (Maranto, 1994), while 
PRKCBP1 (protein kinase C binding protein 1) 
functions as an anchor for activated protein kinase 
C isoenzymes (Fossey et al. 2000). At present, the 
precise role of the PKC transduction pathway in 
the cellular response to cisplatin is yet to be fully 
clariﬁ  ed (Grunicke et al. 2003; Hayakawa et al. 
1999). However, the cisplatin-enhanced expression 
of NMB, ITPR3 and PRKCBP1 in the current study 
may shed light on some of the key factors involved. 
Moreover, the absence of these expression events 
in the response to transplatin damage suggests a 
possible role for the phosphoinositide cascade in 
cisplatin’s cytotoxic mechanism.
At least three transcripts among those speciﬁ  -
cally up-regulated by cisplatin had established or 
tentative growth suppressing properties: GAS1 
(growth arrest speciﬁ  c 1), CDX1 (caudal type 
homeobox transcription factor 1) and AIM1 (absent 
in melanoma 1). GAS1 is an integral plasma mem-
brane protein directly involved in the negative 
regulation of cell proliferation and, in some cases, 
apoptosis (Del Sal et al. 1995; Evdokiou and 
Cowled, 1998; Zamorano et al. 2004). CDX1 
encodes an intestine-speciﬁ  c transcription factor 
that demonstrates both pro-oncogenic functions 
and growth-inhibitory effects (Domon-Dell et al. 
2003; Lynch et al. 2003). AIM1, a novel non-lens 
member of the betagamma-crystallin superfamily, 
is a putative suppressor of human malignant 
melanoma and is associated with the control and 
experimental reversal of tumourigenicity (Ray 
et al. 1997). To date, GAS1, CDX1 and AIM1 have 
not been implicated in the response of cells to 
cisplatin damage.
In contrast, cisplatin-induced transcripts that 
have been shown to inﬂ  uence cell growth in a 
positive manner include CDC25B, G0S2 and 
AGER. CDC25B (cell division cycle 25B) and 
G0S2 (putative lymphocyte G0/G1 switch gene) 
both exert their most prominent effects through the 
regulation of the cell cycle. CDC25B and other 
CDC25 genes encode protein threonine/tyrosine 
phosphatases that drive cell cycle progression 
through the activation of cyclin dependent kinases. 
With obvious growth-promoting properties, 
CDC25B over-expression has been demonstrated 
in a number of cancers including head, neck, gas-
tric, ovarian, esophageal and prostate tumours, as 
well as non Hodgkin’s lymphoma (Broggini et al. 
2000; Gasparotto et al. 1997; Hernandez et al. 
1998; Kishi et al. 2002; Kudo et al. 1997; Miyata 
et al. 2000; Ngan et al. 2003). While the precise 
function of G0S2 is yet to be established, its major 
role in cell cycle regulation is believed to involve 
the switch of lymphocytes from G0 to G1 phases 
(Cristillo et al. 1997; Russell and Forsdyke, 1991). 
AGER (advanced glycosylation end product-
speciﬁ  c receptor), or RAGE, is generally a tumour-
associated antigen and has been shown to stimulate 
cell proliferation and survival (Adams et al. 2002; 
Arumugam et al. 2004; Eichmuller et al. 2002; 
Hsieh et al. 2003). Also, at least one study has 
implicated AGER in the up-regulation of the 
pro-inﬂ  ammatory cytokine IL-6 (Dukic-Stefanovic 
et al. 2003), which was also induced in the current 
study.
Genes speciﬁ  cally down-regulated 
in response to cisplatin
Within this study, many of the transcripts found to 
be speciﬁ  cally down-regulated in response to cis-
platin (Table 8) appeared to be more consistently 
associated with tumour-promoting or growth-
stimulating effects. This finding is significant 
because the relative inhibition of such effects via 
decreased gene expression could contribute to the 
efficient anti-tumour mechanism of cisplatin. 
Among the down-regulated transcripts, genes that 
have been speciﬁ  cally linked with the potential for 
promoting growth and/or proliferation include: 
ephrin-B2 (EFNB2), angiopoietin-like 4 (ANG-
PTL4), diphtheria toxin receptor (DTR) and splic-
ing factor proline/glutamine rich (SFPQ). Such 
associations are outlined brieﬂ  y, below.
The ephrin-B2 gene encodes a member of the 
ephrin (EPH) family which, along with the EPH-
related receptors, comprise a large subfamily of 
receptor protein-tyrosine kinases (Bennett et al. 
1995). Members have been most strongly been 
implicated in mediating developmental events, 
particularly in the central nervous system (Takasu 
et al. 2002) and in erythropoiesis (Suenobu et al. 
2002). EFNB2 expression has also been associated 
with cellular proliferation (Batlle et al. 2002; Steinle 
et al. 2003), cell migration (Steinle et al. 2003), 
angiogenesis (Noren et al. 2004) and the progression 
of a wide range of human cancers, including malig-
nant melanoma (Vogt et al. 1998), small cell lung 
carcinoma (Tang et al. 1999), osteosarcoma (Vare-
lias et al. 2002), endometrial cancer (Takai et al. 
2001), colon/colorectal carcinoma (Liu et al. 2004) 350
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and breast cancer (Noren et al. 2004). In fact, the 
capacity of the EFNB2 ligand to increase the poten-
tial for growth, tumourigenicity and metastasis in 
many of these tumour cells is becoming increasingly 
apparent (Noren et al. 2004; Takai et al. 2001; Vogt 
et al. 1998).
The ANGPTL4 gene encodes an angiopoietin-
like secreted glycoprotein (Kim et al. 2000; Yoon 
et al. 2000). It is one of the targets of the nuclear 
receptor, peroxisome proliferator-activated recep-
tor gamma (PPARgamma), and has proposed roles 
in adipose differentiation, lipid metabolism, glu-
cose homeostasis and angiogenesis (Chen et al. 
2004; Kersten et al. 2000; Le Jan et al. 2003; Lee 
and Evans, 2002; Schmuth et al. 2004; Yoon et al. 
2000; Zhu et al. 2002). Like EFNB2, ANGPTL4 
has also been associated with the development of 
a range of cancers, including colorectal cancer, 
renal cell carcinoma, bladder tumours and gastric 
cancer (Kaneda et al. 2002; Landi et al. 2003; Le 
Jan et al. 2003; Yoshimura et al. 2003).
DTR, also known as the heparin-binding EGF-
like growth factor (HB-EGF), encodes a transmem-
brane protein that interacts with membrane protein 
DRAP27/CD9 to form the functional diphtheria 
toxin receptor (Fen et al. 1993; Hayes et al. 1987; 
Higashiyama et al. 1995; Iwamoto et al. 1994). In 
keeping with the growth-promoting characteristics 
of other down-regulated transcripts in this study, 
DTR demonstrates growth factor activity and 
mitogenic activity (Higashiyama et al. 1991; 
Higashiyama et al. 1995). The capacity of the 
diphtheria toxin receptor to stimulate cell migration 
and proliferation has also been documented 
(Higashiyama et al. 1991; Iivanainen et al. 2003; 
Kiso et al. 2003), as has its contribution to the 
tumourigenesis of gastric epithelial cell cancers 
(Murayama et al. 2002; Wallasch et al. 2002).
SFPQ (splicing factor proline/glutamine rich) 
is a novel and essential pre-mRNA splicing factor 
(Patton et al. 1993). It has been implicated in 
both early and late steps of pre-mRNA splicing 
and is required in spliceosome formation (Patton 
et al. 1993). With a number of roles in various 
nuclear processes, SFPQ has also been linked 
with virally-mediated steroidogenesis and 
oncogenesis (Song et al. 2004). Another positive 
association with cellular proliferation is the 
DNA-pairing activity exhibited by this protein, 
which has been directly implicated in the re-
establishment of stalled replication forks 
(Akhmedov and Lopez, 2000).
Among the remaining transcripts in this study 
with reduced expression levels in response to cis-
platin exposure, the metallothionein-1L (MT1L) 
and transferrin receptor (TFRC) genes have been 
most thoroughly studied and characterised. 
Although not directly associated with the promo-
tion of cell growth, MT1L and TFRC respectively 
play major roles in metal detoxiﬁ  cation and iron 
metabolism, both of which are essential cellular 
processes. Furthermore, the relative effect of cis-
platin treatment on MT1L and TFRC has already 
been addressed in a number of studies, as discussed 
below.
Metallothioneins are intracellular metal-binding 
proteins that are generally found to confer drug 
resistance when induced in tumour tissues. 
Metallothionein-mediated cisplatin resistance, for 
instance, is well documented (Bakka et al. 1981; 
Basu and Lazo, 1990; Endresen and Rugstad, 1987; 
Kelland et al. 1992; Satoh et al. 1994; Suganuma 
et al. 2003; Yang et al. 1994). Although cisplatin 
has also been found to induce metallothionein 
expression in tumour cells (Bauman et al. 1991; 
Farnworth et al. 1989; Harford and Sarkar, 1989; 
Kondo et al. 2003; Matsumoto et al. 1997; Singh 
and Koropatnick, 1988; Zhang et al. 1995), induc-
tion appears to be dependent on the protein isoform 
and the drug-resistant status of the cells (Kinsler 
and Bell, 1985; Nakano et al. 2003). Furthermore, 
metallothionein has also been shown to exhibit a 
biphasic transcriptional response to DNA damage 
in which early expression levels are largely 
depressed (Hansen et al. 1997). In considering 
these observations, it is thus possible that reduced 
metallothionein expression could contribute to 
early drug-induced anti-proliferative effects by 
lessening the chemo-protection that is usually 
afforded by increased metallothionein levels. In 
further support of the ﬁ  ndings reported in this 
thesis, comparative studies with cisplatin and 
transplatin have shown that the inactive isomer 
interacts at a signiﬁ  cantly faster rate with metallo-
thionein, and does not appear to induce its biosyn-
thesis (Farnworth et al. 1989; Harford and Sarkar, 
1989; Zelazowski et al. 1984; Zhang et al. 1995).
As introduced above, the transferrin receptor 
gene, TFRC, encodes a glycoprotein with an essen-
tial role in iron metabolism (Omary and Trowbridge, 
1981; Schneider et al. 1984). Several interesting 
relationships between cisplatin and TFRC have 
also been revealed. Firstly, the ability of cisplatin 
to bind transferrin is well established, and there is 351
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evidence that the cisplatin-transferrin complex can 
be transported into cells via the transferrin receptor 
(Allardyce et al. 2002; Gullo et al. 1980; Hamada 
1988; Head et al. 1997; Sykes et al. 1985). In 
another study, cisplatin-induced transferrin modu-
lation was found to be accompanied by severe 
spermatogenic damage in rat testes (Nambu and 
Kumamoto, 1995). This observation may be sig-
niﬁ  cant because it has the potential to provide 
insight into the enhanced sensitivity of testicular 
carcinomas to cisplatin-based therapies.
Various studies have also documented the 
reduced expression of TFRC mRNA after cisplatin 
treatment (Marazzi et al. 1991; Parodi et al. 1988; 
Tonini et al. 1986), an observation that is consistent 
with the ﬁ  ndings reported in the current study. 
Moreover, Marazzi and colleagues (1991) observed 
that this effect correlated well with low TFRC 
protein expression and the inhibition of DNA syn-
thesis and cellular proliferation. Conversely, a 
number of studies have reported a distinct correla-
tion between higher levels of TFRC expression and 
increased cellular proliferation in cancer cells 
(Miyamoto, 1992; Moura et al. 2004; Staber et al. 
2004). Together, these ﬁ  ndings suggest a more 
deﬁ  ned role for TFRC in promoting cellular growth 
and proliferation – again, a common theme among 
the genes down-modulated by cisplatin in this 
study. Overall, the connection between TFRC and 
cisplatin damage is potentially an interesting one, 
and certainly worthy of further study.
Conclusion
In conclusion, the current study has utilised 
microarrays to identify a number of genes that are 
differentially expressed in human cells in response 
to cisplatin and transplatin treatments. However, 
the functional interpretation of transcriptional 
events revealed by microarray analysis still 
presents a major challenge. Researching the 
known properties and functions of such genes is 
indeed a small but important step towards 
understanding their biological relevance in the 
experimental context of interest. In the present 
study, such investigations provided insight into 
several gene expression responses that are 
uniquely elicited by cisplatin with respect to its 
clinically ineffective isomer, transplatin. This data 
has indicted a number of genes that would be 
strong candidates for further gene function 
analysis that can mimic the effect of cisplatin at 
the gene expression level.
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